Eagle Pharmaceuticals, Inc. EGRX
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -5.38% | 8.48% | 84.56% | 66.48% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.38% | 8.48% | 84.56% | 66.48% | -- |
| Cost of Revenue | 7.90% | 42.99% | 125.07% | 106.02% | -- |
| Gross Profit | -10.15% | -2.42% | 71.35% | 54.21% | -- |
| SG&A Expenses | 27.77% | 21.49% | 17.53% | 10.46% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.66% | 20.15% | 28.90% | 15.24% | -- |
| Operating Income | -44.71% | -23.15% | 3,477.46% | 2,220.27% | -- |
| Income Before Tax | -27.72% | -72.95% | 1,450.77% | 778.95% | -- |
| Income Tax Expenses | -1.96% | 4.71% | 532.29% | 255,300.00% | -- |
| Earnings from Continuing Operations | -47.57% | -107.44% | 513.14% | 278.26% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.57% | -107.44% | 513.14% | 278.26% | -- |
| EBIT | -44.71% | -23.15% | 3,477.46% | 2,220.27% | -- |
| EBITDA | -21.99% | -3.51% | 1,601.39% | 1,244.54% | -- |
| EPS Basic | -49.41% | -107.42% | 522.14% | 297.21% | -- |
| Normalized Basic EPS | -47.21% | -40.59% | 9,251.50% | 2,612.73% | -- |
| EPS Diluted | -48.40% | -108.02% | 508.55% | 297.88% | -- |
| Normalized Diluted EPS | -46.83% | -39.92% | 10,482.56% | 2,836.89% | -- |
| Average Basic Shares Outstanding | 1.58% | 0.55% | -0.81% | -1.36% | -- |
| Average Diluted Shares Outstanding | 1.71% | 0.26% | -0.52% | -1.77% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |